Literature DB >> 35892095

Ocular manifestations of Nabais Sa-de Vries Syndrome type 1.

Liuzhi Zhang1, Kayla King2, Natario L Couser2,3,4.   

Abstract

Nabais Sa-de Vries syndrome (NSDVS) is a neurodevelopmental disorder first described in 2020. The syndrome is caused by de novo missense mutations in speckle-type pox virus and zinc finger protein (SPOP) on chromosome 17q21. The syndrome is divided into two forms (NSDVS Type 1 and NSDVS Type 2) based on the consequence of the mutation involved. In this report, we present the clinical features in a young male patient with suspected NSDVS1 and summarize the features of the reported affected individuals thus far, with a focus on the ophthalmic manifestations. Similar to other individuals with NSDVS1, he had features of congenital microcephaly, developmental delay, behavioral abnormalities, hearing loss, and facial dysmorphisms. Ocular and periorbital manifestations in this patient included thick high-arched eyebrows, mild synophrys, long eyelashes, ptosis, and downslanting palpebral fissures; comparable to features described in other individuals with NSDVS1. In addition, this patient had esotropia that required multiple strabismus surgeries and a refractive error that required the use of corrective lenses. Although the consequences of specific mutations may result in a portion of the phenotypic differences between NSDVS1 and NSDVS2, the ophthalmic abnormalities between the two types may have significant overlap not explained by these bidirectional mutational effects. IJMEG
Copyright © 2022.

Entities:  

Keywords:  NSDVS1; NSDVS2; Nabais Sa-de Vries Syndrome; SPOP; craniofacial dysmorphisms; microcephaly; neurodevelopmental disorder

Year:  2022        PMID: 35892095      PMCID: PMC9301176     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  5 in total

1.  De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders.

Authors:  Maria J Nabais Sá; Geniver El Tekle; Arjan P M de Brouwer; Sarah L Sawyer; Daniela Del Gaudio; Michael J Parker; Farah Kanani; Marie-José H van den Boogaard; Koen van Gassen; Margot I Van Allen; Klaas Wierenga; Gabriela Purcarin; Ellen Roy Elias; Amber Begtrup; Jennifer Keller-Ramey; Tiziano Bernasocchi; Laurens van de Wiel; Christian Gilissen; Hanka Venselaar; Rolph Pfundt; Lisenka E L M Vissers; Jean-Philippe P Theurillat; Bert B A de Vries
Journal:  Am J Hum Genet       Date:  2020-02-27       Impact factor: 11.025

Review 2.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

3.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

4.  Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Authors:  Hana Janouskova; Geniver El Tekle; Elisa Bellini; Namrata D Udeshi; Anna Rinaldi; Anna Ulbricht; Tiziano Bernasocchi; Gianluca Civenni; Marco Losa; Tanya Svinkina; Craig M Bielski; Gregory V Kryukov; Luciano Cascione; Sara Napoli; Radoslav I Enchev; David G Mutch; Michael E Carney; Andrew Berchuck; Boris J N Winterhoff; Russell R Broaddus; Peter Schraml; Holger Moch; Francesco Bertoni; Carlo V Catapano; Matthias Peter; Steven A Carr; Levi A Garraway; Peter J Wild; Jean-Philippe P Theurillat
Journal:  Nat Med       Date:  2017-08-14       Impact factor: 53.440

5.  Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

Authors:  Pingzhao Zhang; Dejie Wang; Yu Zhao; Shancheng Ren; Kun Gao; Zhenqing Ye; Shangqian Wang; Chun-Wu Pan; Yasheng Zhu; Yuqian Yan; Yinhui Yang; Di Wu; Yundong He; Jun Zhang; Daru Lu; Xiuping Liu; Long Yu; Shimin Zhao; Yao Li; Dong Lin; Yuzhuo Wang; Liguo Wang; Yu Chen; Yinghao Sun; Chenji Wang; Haojie Huang
Journal:  Nat Med       Date:  2017-08-14       Impact factor: 53.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.